Danicopan
- Generic Name
- Danicopan
- Brand Names
- Voydeya
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23BrFN7O3
- CAS Number
- 1903768-17-1
- Unique Ingredient Identifier
- JM8C1SFX0U
- Background
Danicopan is under investigation in clinical trial NCT03459443 (A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)).
- Associated Conditions
- -
- Associated Therapies
- -
A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
- First Posted Date
- 2017-04-21
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03124368
- Locations
- 🇳🇱
Clinical Trial Site, Leiden, Netherlands
A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2021-06-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03108274
- Locations
- 🇳🇿
Clinical Trial Site, Auckland, New Zealand
Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT03053102
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath